当前位置:首页 - 行情中心 - 华森制药(002907) - 财务分析 - 利润表

华森制药

(002907)

  

流通市值:57.30亿  总市值:77.46亿
流通股本:3.09亿   总股本:4.18亿

利润表

报告期2025-03-312024-12-312024-09-302024-06-30
公司类型通用通用通用通用
一、营业总收入238,944,153.42774,819,866.89614,223,361.57417,852,265.17
  营业收入238,944,153.42774,819,866.89614,223,361.57417,852,265.17
二、营业总成本189,330,193.11699,830,140.66534,304,062.41361,848,490.3
  营业成本97,438,325.28331,050,582.43259,861,828.77175,944,194.61
  税金及附加2,554,236.9612,105,852.917,833,077.476,051,458.26
  销售费用68,872,834.62250,533,803.89196,181,589.06133,698,419.66
  管理费用12,696,210.9957,827,627.9341,032,795.927,768,062.4
  研发费用12,304,890.5859,129,476.8938,987,662.3825,843,637.72
  财务费用-4,536,305.32-10,817,203.39-9,592,891.17-7,457,282.35
  其中:利息费用1,507.67-518,913.86-344,416.84,338.7
  其中:利息收入4,603,017.8510,321,090.559,333,877.677,513,021.29
三、其他经营收益
  加:公允价值变动收益471,129.477,518,348.83437,865.0690,100.79
  加:投资收益-811,330.04-6,140,731.36-3,438,914.87-2,836,418.72
  资产减值损失(新)-86,852.9-1,859,620.57-1,068,293.84-397,153.79
  信用减值损失(新)-2,014,007.51-1,635,836.57-3,861,266.09-2,198,119.49
  其他收益2,348,546.5620,928,702.9417,066,173.966,976,770.02
四、营业利润49,521,445.8993,800,589.589,054,863.3857,638,953.68
  加:营业外收入24,571.01208,049.11202,728.9575,142.94
  减:营业外支出244,679.28566,699.92584,723.52513,852.35
五、利润总额49,301,337.6293,441,938.6988,672,868.8157,200,244.27
  减:所得税费用8,946,125.2416,711,713.5714,096,033.189,985,348.15
六、净利润40,355,212.3876,730,225.1274,576,835.6347,214,896.12
(一)按经营持续性分类
  持续经营净利润40,355,212.3876,730,225.1274,576,835.6347,214,896.12
(二)按所有权归属分类
  归属于母公司股东的净利润40,355,212.3876,730,225.1274,576,835.6347,214,896.12
  扣除非经常损益后的净利润37,667,440.4551,210,295.7260,023,312.841,552,611.25
七、每股收益
  (一)基本每股收益0.10.180.180.11
  (二)稀释每股收益0.10.180.180.11
八、其他综合收益-6,070.86244,061.74-173,845.46101,866.35
  归属于母公司股东的其他综合收益-6,070.86244,061.74-173,845.46101,866.35
九、综合收益总额40,349,141.5276,974,286.8674,402,990.1747,316,762.47
  归属于母公司股东的综合收益总额40,349,141.5276,974,286.8674,402,990.1747,316,762.47
公告日期2025-04-252025-04-252024-10-292024-08-22
审计意见(境内)标准无保留意见
TOP↑